The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

tartrate     2,3-dihydroxybutanedioic acid

Synonyms: Traubensaure, DL-Tartrate, Threaric acid, tartaric acid, WLN: QVYQYQVQ, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of tartaric acid

 

Psychiatry related information on tartaric acid

 

High impact information on tartaric acid

 

Chemical compound and disease context of tartaric acid

  • Pretreatment of CDR rats with a 5-HT2 receptor antagonist (ketanserin tartrate, 2 mg/kg, i.v.) before episodic hypoxia prevented long-term facilitation and revealed a modest (-28 +/- 13%; p < 0.05) long-lasting depression of phrenic motor output [15].
  • BACKGROUND: The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation [6].
  • Both the biochemical indices of bone resorption (urinary hydroxyproline/creatinine ratio and plasma tartrate-resistant acid phosphatase) and bone formation (serum osteocalcin and bone isoenzyme of alkaline phosphatase) were significantly increased in the patients compared with healthy controls [16].
  • Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers [17].
  • Bone resorption could not completely account for this effect, because resorption markers (tartrate-resistant acid phosphatase 5b, urinary deoxypyridinoline excretion, and tartrate-resistant acid phosphatase 5 mRNA) are unchanged or reduced at 2 and/or 4 wk after diabetes induction [18].
 

Biological context of tartaric acid

 

Anatomical context of tartaric acid

 

Associations of tartaric acid with other chemical compounds

  • Elucidation of the reactions relating L-tartaric acid to vitamin C catabolism in the Vitaceae showed that they proceed via the oxidation of L-idonic acid, the proposed rate-limiting step in the pathway [5].
  • Inhibition of a tartrate-resistant acid phosphatase (ACP) from Leishmania donovani and the tartrate-sensitive ACP from human seminal fluid (prostatic ACP) was examined using a series of 13 molybdate-containing heteropolyanions [28].
  • In several experiments with the addition of glycolipids to D-PDMP-treated purified bone marrow cells, lactosylceramide (LacCer) strongly affected the differentiation into tartrate-resistant acid phosphatase mononucleated cells, but not positive multinucleated cells [29].
  • Previous crystallographic studies compiled on the tartrate-rat prostatic acid phosphatase binary complex (Lindqvist, Y., Schneider, G., and Vihko, P. (1993) J. Biol. Chem. 268, 20744-20746) erroneously positioned D-tartrate into the active site [30].
  • Osteoblastic tartrate-resistant acid phosphatase: its potential role in the molecular mechanism of osteogenic action of fluoride [31].
 

Gene context of tartaric acid

  • Overlapping functions of lysosomal acid phosphatase (LAP) and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient mice [32].
  • Comparison of arthritic mice from the AdIL-17 collagen-induced arthritis group with full-blown collagen-arthritic mice having similar clinical scores for joint inflammation revealed lower RANKL/OPG ratio and tartrate-resistant acid phosphatase activity in the latter group [33].
  • In murine bone marrow cultures, TGF-beta1 markedly inhibited the formation of tartrate-resistant acid phosphatase-positive multinucleated osteoclast-like cells in the presence of 1,25-dihydroxyvitamin D3, whose effect was significantly reversed by a neutralizing antibody against OPG/OCIF [34].
  • MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption [35].
  • 5) Up-regulation of tartrate-resistant acid phosphatase-positive multinuclear cell formation by beta1 stimulation was completely abrogated by transfection of dominant negative truncations of FAK [36].
 

Analytical, diagnostic and therapeutic context of tartaric acid

  • Since vinorelbine tartrate and paclitaxel have shown a similar antitumor profile in clinical trials thus far, it is reasonable to expect that they may be used interchangeably in some combination therapies or perhaps with each other in the same treatment regimen [1].
  • There are no totally specific markers for this cell, although tartrate-resistant acid phosphatase staining has been used extensively as a diagnostic test [37].
  • CONCLUSIONS: Results suggest that the overlapping toxic effects of vinorelbine tartrate and paclitaxel might not be a deterrent to their use in combination drug therapy [1].
  • Hairy cell identification by immunohistochemistry of tartrate-resistant acid phosphatase [38].
  • Molecular dissection of the functional domains of a unique, tartrate-resistant, surface membrane acid phosphatase in the primitive human pathogen Leishmania donovani [39].

References

  1. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. Knick, V.C., Eberwein, D.J., Miller, C.G. J. Natl. Cancer Inst. (1995) [Pubmed]
  2. Immortalization of osteoclast precursors by targeting Bcl -XL and Simian virus 40 large T antigen to the osteoclast lineage in transgenic mice. Hentunen, T.A., Reddy, S.V., Boyce, B.F., Devlin, R., Park, H.R., Chung, H., Selander, K.S., Dallas, M., Kurihara, N., Galson, D.L., Goldring, S.R., Koop, B.A., Windle, J.J., Roodman, G.D. J. Clin. Invest. (1998) [Pubmed]
  3. Tolfenamic acid is as effective as ergotamine during migraine attacks. Hakkarainen, H., Vapaatalo, H., Gothoni, G., Parantainen, J. Lancet (1979) [Pubmed]
  4. Ischemic bowel disease attributable to ergot. Stillman, A.E., Weinberg, M., Mast, W.C., Palpant, S. Gastroenterology (1977) [Pubmed]
  5. L-tartaric acid synthesis from vitamin C in higher plants. DeBolt, S., Cook, D.R., Ford, C.M. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  6. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., Billing, C.B., Anziano, R., Reeves, K. Arch. Intern. Med. (2006) [Pubmed]
  7. Therapeutic usefulness of ergotamine tartrate for narcolepsy. Kaneko, Y., Takahashi, Y., Kaneko, M., Kumashiro, H. The American journal of psychiatry. (1978) [Pubmed]
  8. The effects of phenindamine tartrate on sleepiness and psychomotor performance. Witek, T.J., Canestrari, D.A., Miller, R.D., Yang, J.Y., Riker, D.K. J. Allergy Clin. Immunol. (1992) [Pubmed]
  9. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy. Utsuki, T., Uchimura, N., Irikura, M., Moriuchi, H., Holloway, H.W., Yu, Q.S., Spangler, E.L., Mamczarz, J., Ingram, D.K., Irie, T., Greig, N.H. J. Pharmacol. Exp. Ther. (2007) [Pubmed]
  10. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. da Costa, C.E., Annels, N.E., Faaij, C.M., Forsyth, R.G., Hogendoorn, P.C., Egeler, R.M. J. Exp. Med. (2005) [Pubmed]
  11. RANKL-induced DC-STAMP is essential for osteoclastogenesis. Kukita, T., Wada, N., Kukita, A., Kakimoto, T., Sandra, F., Toh, K., Nagata, K., Iijima, T., Horiuchi, M., Matsusaki, H., Hieshima, K., Yoshie, O., Nomiyama, H. J. Exp. Med. (2004) [Pubmed]
  12. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Morinaga, T., Higashio, K., Martin, T.J., Suda, T. J. Exp. Med. (2000) [Pubmed]
  13. Mononuclear phagocytes have the potential for sustained hydroxyl radical production. Use of spin-trapping techniques to investigate mononuclear phagocyte free radical production. Britigan, B.E., Coffman, T.J., Adelberg, D.R., Cohen, M.S. J. Exp. Med. (1988) [Pubmed]
  14. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M.T., Martin, T.J., Suda, T. J. Clin. Invest. (1999) [Pubmed]
  15. Cervical dorsal rhizotomy enhances serotonergic innervation of phrenic motoneurons and serotonin-dependent long-term facilitation of respiratory motor output in rats. Kinkead, R., Zhan, W.Z., Prakash, Y.S., Bach, K.B., Sieck, G.C., Mitchell, G.S. J. Neurosci. (1998) [Pubmed]
  16. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. Stĕpán, J.J., Lachman, M., Zvĕrina, J., Pacovský, V., Baylink, D.J. J. Clin. Endocrinol. Metab. (1989) [Pubmed]
  17. Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. Waguespack, S.G., Hui, S.L., White, K.E., Buckwalter, K.A., Econs, M.J. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  18. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice. Botolin, S., Faugere, M.C., Malluche, H., Orth, M., Meyer, R., McCabe, L.R. Endocrinology (2005) [Pubmed]
  19. Treatment of chronic orthostatic hypotension with ergotamine. Chobanian, A.V., Tifft, C.P., Faxon, D.P., Creager, M.A., Sackel, H. Circulation (1983) [Pubmed]
  20. Polyclonal B-cell lymphocytosis with features resembling hairy cell leukemia-Japanese variant. Machii, T., Yamaguchi, M., Inoue, R., Tokumine, Y., Kuratsune, H., Nagai, H., Fukuda, S., Furuyama, K., Yamada, O., Yahata, Y., Kitani, T. Blood (1997) [Pubmed]
  21. Inhibition of tartrate-resistant acid phosphatase gene expression by hemin and protoporphyrin IX. Identification of a hemin-responsive inhibitor of transcription. Reddy, S.V., Alcantara, O., Roodman, G.D., Boldt, D.H. Blood (1996) [Pubmed]
  22. CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Hanson, C.A., Gribbin, T.E., Schnitzer, B., Schlegelmilch, J.A., Mitchell, B.S., Stoolman, L.M. Blood (1990) [Pubmed]
  23. Isolation of a murine osteoclast colony-stimulating factor. Lee, M.Y., Eyre, D.R., Osborne, W.R. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  24. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Michigami, T., Shimizu, N., Williams, P.J., Niewolna, M., Dallas, S.L., Mundy, G.R., Yoneda, T. Blood (2000) [Pubmed]
  25. Generation of CD1+RelB+ dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Akagawa, K.S., Takasuka, N., Nozaki, Y., Komuro, I., Azuma, M., Ueda, M., Naito, M., Takahashi, K. Blood (1996) [Pubmed]
  26. Defective bone mineralization and osteopenia in young adult FGFR3-/- mice. Valverde-Franco, G., Liu, H., Davidson, D., Chai, S., Valderrama-Carvajal, H., Goltzman, D., Ornitz, D.M., Henderson, J.E. Hum. Mol. Genet. (2004) [Pubmed]
  27. Acid phosphatase activity in mononuclear phagocytes and the U937 cell line: monocyte-derived macrophages express tartrate-resistant acid phosphatase. Snipes, R.G., Lam, K.W., Dodd, R.C., Gray, T.K., Cohen, M.S. Blood (1986) [Pubmed]
  28. Inhibition of human seminal fluid and Leishmania donovani phosphatases by molybdate heteropolyanions. Saha, A.K., Crans, D.C., Pope, M.T., Simone, C.M., Glew, R.H. J. Biol. Chem. (1991) [Pubmed]
  29. Lactosylceramide is essential for the osteoclastogenesis mediated by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappa B ligand. Iwamoto, T., Fukumoto, S., Kanaoka, K., Sakai, E., Shibata, M., Fukumoto, E., Inokuchi Ji, J., Takamiya, K., Furukawa, K., Furukawa, K., Kato, Y., Mizuno, A. J. Biol. Chem. (2001) [Pubmed]
  30. Structural origins of L(+)-tartrate inhibition of human prostatic acid phosphatase. LaCount, M.W., Handy, G., Lebioda, L. J. Biol. Chem. (1998) [Pubmed]
  31. Osteoblastic tartrate-resistant acid phosphatase: its potential role in the molecular mechanism of osteogenic action of fluoride. Lau, K.H., Baylink, D.J. J. Bone Miner. Res. (2003) [Pubmed]
  32. Overlapping functions of lysosomal acid phosphatase (LAP) and tartrate-resistant acid phosphatase (Acp5) revealed by doubly deficient mice. Suter, A., Everts, V., Boyde, A., Jones, S.J., Lüllmann-Rauch, R., Hartmann, D., Hayman, A.R., Cox, T.M., Evans, M.J., Meister, T., von Figura, K., Saftig, P. Development (2001) [Pubmed]
  33. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. Lubberts, E., van den Bersselaar, L., Oppers-Walgreen, B., Schwarzenberger, P., Coenen-de Roo, C.J., Kolls, J.K., Joosten, L.A., van den Berg, W.B. J. Immunol. (2003) [Pubmed]
  34. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashio, K., Ikeda, K., Watanabe, K., Yamada, Y. J. Biol. Chem. (1998) [Pubmed]
  35. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption. Kim, M.S., Day, C.J., Selinger, C.I., Magno, C.L., Stephens, S.R., Morrison, N.A. J. Biol. Chem. (2006) [Pubmed]
  36. Beta1 integrin/focal adhesion kinase-mediated signaling induces intercellular adhesion molecule 1 and receptor activator of nuclear factor kappaB ligand on osteoblasts and osteoclast maturation. Nakayamada, S., Okada, Y., Saito, K., Tamura, M., Tanaka, Y. J. Biol. Chem. (2003) [Pubmed]
  37. Monoclonal antibodies with specificity for hairy cell leukemia cells. Posnett, D.N., Chiorazzi, N., Kunkel, H.G. J. Clin. Invest. (1982) [Pubmed]
  38. Hairy cell identification by immunohistochemistry of tartrate-resistant acid phosphatase. Janckila, A.J., Cardwell, E.M., Yam, L.T., Li, C.Y. Blood (1995) [Pubmed]
  39. Molecular dissection of the functional domains of a unique, tartrate-resistant, surface membrane acid phosphatase in the primitive human pathogen Leishmania donovani. Shakarian, A.M., Joshi, M.B., Ghedin, E., Dwyer, D.M. J. Biol. Chem. (2002) [Pubmed]
 
WikiGenes - Universities